PMID- 22156484
OWN - NLM
STAT- MEDLINE
DCOM- 20120503
LR  - 20131121
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 84 Suppl 1
DP  - 2011
TI  - HLA-DRB1*010101 allele is closely associated with poor virological response to 
      lamivudine therapy in patients with chronic hepatitis B.
PG  - 35-42
LID - 10.1159/000333783 [doi]
AB  - BACKGROUND/AIMS: We intended to evaluate the association between specific human 
      leukocyte antigen (HLA)-DRB1 gene polymorphism and antiviral response to 
      lamivudine (LAM) therapy in chronic hepatitis B (CHB) patients. METHODS: 
      Six-digit HLA-DRB1 genotypes were determined using sequence-based typing in 334 
      CHB patients initially treated with LAM for at least 12 months. Antiviral 
      response was evaluated every 3-6 months during LAM therapy. RESULTS: Median age 
      of the subjects was 43 years (range, 16-72). Median duration of LAM therapy was 
      69 months (range, 13-140). Median baseline serum hepatitis B virus (HBV DNA) 
      level was 7.0 log(10) copies/ml (range, 5.5-9.1). At 12 months of LAM therapy, 
      serum HBV DNA was undetectable by solution hybridization method in 308 (88%) 
      patients. Among 25 HLA-DRB1 alleles identified, HLA-DRB1*090102, *080302, and 
      *070101 were the most frequent alleles (>10%). HLA-DRB1*010101 was identified in 
      5.4% (18/334). The frequency of the HLA-DRB1*010101 allele was significantly 
      lower in patients with virological response at 12 months of LAM therapy than in 
      patients without it (4.2 vs. 19.2%, p = 0.025). The other HLA-DRB1 alleles were 
      not associated with virological response. HBeAg loss/seroconversion and alanine 
      aminotransferase normalization were not associated with HLA-DRB1 alleles. 
      CONCLUSION: The HLA-DRB1*010101 allele is closely associated with poor 
      virological response to initial LAM therapy in CHB patients.
CI  - Copyright (c) 2011 S. Karger AG, Basel.
FAU - Jin, Young-Joo
AU  - Jin YJ
AD  - Department of Internal Medicine, University of Ulsan College of Medicine, Asan 
      Medical Center, Seoul, Korea.
FAU - Shim, Ju Hyun
AU  - Shim JH
FAU - Chung, Young-Hwa
AU  - Chung YH
FAU - Kim, Jeong A
AU  - Kim JA
FAU - Choi, Jong Gi
AU  - Choi JG
FAU - Park, Won Hyung
AU  - Park WH
FAU - Lee, Danbi
AU  - Lee D
FAU - Kim, Sung Eun
AU  - Kim SE
FAU - Lee, Yoon Seon
AU  - Lee YS
FAU - Kim, Sung Hoon
AU  - Kim SH
FAU - Yang, Soo Hyun
AU  - Yang SH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111202
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA Primers)
RN  - 0 (DNA, Viral)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Hepatitis B e Antigens)
RN  - 2T8Q726O95 (Lamivudine)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Alanine Transaminase/blood
MH  - Antiviral Agents/*therapeutic use
MH  - Cohort Studies
MH  - DNA Primers/chemistry
MH  - DNA, Viral/blood
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - HLA-DRB1 Chains/*genetics
MH  - Hepatitis B e Antigens/blood
MH  - Hepatitis B virus/*isolation & purification
MH  - Hepatitis B, Chronic/*drug therapy/*genetics/virology
MH  - Humans
MH  - Lamivudine/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic
MH  - Retrospective Studies
MH  - Young Adult
EDAT- 2011/12/22 06:00
MHDA- 2012/05/04 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/22 06:00 [pubmed]
PHST- 2012/05/04 06:00 [medline]
AID - 000333783 [pii]
AID - 10.1159/000333783 [doi]
PST - ppublish
SO  - Digestion. 2011;84 Suppl 1:35-42. doi: 10.1159/000333783. Epub 2011 Dec 2.